X-Mozilla-Status: 9001 X-Mozilla-Status2: 00000000 Message-ID: <373A727D.7C9982C8@concentric.net> Disposition-Notification-To: dmfarran@concentric.net Date: Thu, 13 May 1999 01:34:38 -0500 From: dmfarran@concentric.net X-Mailer: Mozilla 4.5 [en] (Win95; U) X-Accept-Language: en MIME-Version: 1.0 To: stricker@epib.fgg.eur.nl Subject: Pharmaco-epidemiology of Sumatriptan Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit Dear Dr. Stricker, I spoke to you via EMail on 1997-08-12 (August 12, 1997) regarding your Thesis on the Pharmaco-epidemiology of Sumatriptan, #1996:033, that you published with Dr. Grobbee, at the Academic Hospital Rotterdam - Dijkzigt, Erasmus University Rotterdam, 1996/03/13. The copy that you sent me was of great use to me.  Thank you very much for sending me it. I have several questions to ask you. Did you ever send a copy of your Thesis, or a copy of your research, or any other information relating to your research to Glaxo, the maker of Sumatriptan? If you did not send this information, do you know if Glaxo ever received this information from anyone or in any way? If Glaxo did receive this information, do you know the date when they became aware of your research? This information is very important to some current research being done into Sumatriptan and the danger of adverse reactions to Sumatriptan here in the United States. Thank you very much for your help with this. Very sincerely yours, David M. Farrand

Return-Path: <stricker@epib.fgg.eur.nl> Received: from mailgate.eur.nl (mailgate.eur.nl [130.115.1.1])      by franklin.concentric.net (8.9.1a/(99/04/26 5.23))      id NAA12166; Tue, 18 May 1999 13:03:43 -0400 (EDT)      [1-800-745-2747 The Concentric Network] Errors-To: <stricker@epib.fgg.eur.nl> Received: from hp750.fgg.eur.nl (hp750.fgg.eur.nl [130.115.152.4])      by mailgate.eur.nl (8.9.3/8.9.3) with SMTP id SAA05243      for <dmfarran@concentric.net>; Tue, 18 May 1999 18:58:37 +0200 (MET DST) Message-ID: <199905181658.SAA05243@mailgate.eur.nl> Received: from ns1.fgg.eur.nl by hp750.fgg.eur.nl with SMTP      (1.38.193.4/16.2) id AA21493; Tue, 18 May 1999 18:58:34 +0200 Received: from NS1-FGG-EUR-NL/SpoolDir by ns1.fgg.eur.nl (Mercury 1.31);      18 May 99 18:58:27 met-1mst Received: from SpoolDir by NS1-FGG-EUR-NL (Mercury 1.31); 18 May 99 18:58:05 met-1mst X-UIDL: 927048448.001 From: "Bruno Stricker" <stricker@epib.fgg.eur.nl> Organization: Erasmus University Rotterdam To: dmfarran@concentric.net Date: Tue, 18 May 1999 18:57:59 MET-1MST Mime-Version: 1.0 Content-Type: text/plain; charset=US-ASCII Content-Transfer-Encoding: 7BIT Subject: Re: Pharmaco-epidemiology of Sumatriptan Reply-To: stricker@epib.fgg.eur.nl X-Confirm-Reading-To: stricker@epib.fgg.eur.nl X-Pmrqc: 1 Priority: normal In-Reply-To: <373A727D.7C9982C8@concentric.net> X-Mailer: Pegasus Mail for Win32 (v2.54) Status: U X-Mozilla-Status: 9011 Dear dr Farrand, Thank you very much for your mail. Actually, the thesis was not mine. I had my PhD on drug-induced hepatic injury in 1987. Dr Ottervanger made the thesis on sumatriptan and defended the thesis early 1995. Glaxo received a copy so since that time they should have been aware of all details. Of course, they were not too happy about this. Actually, we had some arguments with them and they tried to pursuade the Lancet not to publish the case-report of the patient with myocardial infarction. Luckily, the Lancet published the case in 1993. Anyhow, let me know if I can be of any further help. Sincerely yours, Bruno Stricker